Associations between serum Vitamin D and adverse pathology in men undergoing radical prostatectomy

Yaw A. Nyame, Adam B. Murphy*, Diana K. Bowen, Gregory Jordan, Ken Batai, Michael Dixon, Courtney M.P. Hollowell, Stephanie Kielb, Joshua J. Meeks, Peter H. Gann, Virgilia Macias, Andre Kajdacsy-Balla, William J. Catalona, Rick Kittles

*Corresponding author for this work

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Purpose Lower serum Vitamin D levels have been associated with an increased risk of aggressive prostate cancer. Among men with localized prostate cancer, especially with low- or intermediate-risk disease, Vitamin D may serve as an important biomarker of disease aggression. The aim of this study was to assess the relationship between adverse pathology at the time of radical prostatectomy and serum 25-hydroxyVitamin D (25-OH D) levels. Methods This cross-sectional study was carried out from 2009 to 2014, nested within a large epidemiologic study of 1,760 healthy controls and men undergoing prostate cancer screening. In total, 190 men underwent radical prostatectomy in the cohort. Adverse pathology was defined as the presence of primary Gleason 4 or any Gleason 5 disease, or extraprostatic extension. Descriptive and multivariate analyses were performed to assess the relationship between 25-OH D and adverse pathology at the time of prostatectomy. Results Eighty-seven men (45.8%) in this cohort demonstrated adverse pathology at radical prostatectomy. Themedian age in the cohort was 64.0 years (interquartile range, 59.0 to 67.0). On univariate analysis,men with adverse pathology at radical prostatectomy demonstrated lower median serum 25-OH D (22.7 v 27.0 ng/mL, P = .007) comparedwith their counterparts. On multivariate analysis, controlling for age, serum prostate specific antigen, and abnormal digital rectal examination, serum 25-OH D less than 30 ng/mL was associated with increased odds of adverse pathology (odds ratio, 2.64; 95% CI, 1.25 to 5.59; P = .01). Conclusion Insufficiency/deficiency of serum 25-OH D is associated with increased odds of adverse pathology in men with localized disease undergoing radical prostatectomy. Serum 25-OH D may serve as a useful biomarker in prostate cancer aggressiveness, which deserves continued study.

Original languageEnglish (US)
Pages (from-to)1345-1349
Number of pages5
JournalJournal of Clinical Oncology
Volume34
Issue number12
DOIs
StatePublished - Apr 20 2016

Fingerprint

Prostatectomy
Vitamin D
Pathology
Serum
Prostatic Neoplasms
Multivariate Analysis
Biomarkers
Digital Rectal Examination
Prostate-Specific Antigen
Aggression
Early Detection of Cancer
Epidemiologic Studies
Cross-Sectional Studies
Odds Ratio

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Nyame, Yaw A. ; Murphy, Adam B. ; Bowen, Diana K. ; Jordan, Gregory ; Batai, Ken ; Dixon, Michael ; Hollowell, Courtney M.P. ; Kielb, Stephanie ; Meeks, Joshua J. ; Gann, Peter H. ; Macias, Virgilia ; Kajdacsy-Balla, Andre ; Catalona, William J. ; Kittles, Rick. / Associations between serum Vitamin D and adverse pathology in men undergoing radical prostatectomy. In: Journal of Clinical Oncology. 2016 ; Vol. 34, No. 12. pp. 1345-1349.
@article{8b57e64a871c42fea3f737d65197ee01,
title = "Associations between serum Vitamin D and adverse pathology in men undergoing radical prostatectomy",
abstract = "Purpose Lower serum Vitamin D levels have been associated with an increased risk of aggressive prostate cancer. Among men with localized prostate cancer, especially with low- or intermediate-risk disease, Vitamin D may serve as an important biomarker of disease aggression. The aim of this study was to assess the relationship between adverse pathology at the time of radical prostatectomy and serum 25-hydroxyVitamin D (25-OH D) levels. Methods This cross-sectional study was carried out from 2009 to 2014, nested within a large epidemiologic study of 1,760 healthy controls and men undergoing prostate cancer screening. In total, 190 men underwent radical prostatectomy in the cohort. Adverse pathology was defined as the presence of primary Gleason 4 or any Gleason 5 disease, or extraprostatic extension. Descriptive and multivariate analyses were performed to assess the relationship between 25-OH D and adverse pathology at the time of prostatectomy. Results Eighty-seven men (45.8{\%}) in this cohort demonstrated adverse pathology at radical prostatectomy. Themedian age in the cohort was 64.0 years (interquartile range, 59.0 to 67.0). On univariate analysis,men with adverse pathology at radical prostatectomy demonstrated lower median serum 25-OH D (22.7 v 27.0 ng/mL, P = .007) comparedwith their counterparts. On multivariate analysis, controlling for age, serum prostate specific antigen, and abnormal digital rectal examination, serum 25-OH D less than 30 ng/mL was associated with increased odds of adverse pathology (odds ratio, 2.64; 95{\%} CI, 1.25 to 5.59; P = .01). Conclusion Insufficiency/deficiency of serum 25-OH D is associated with increased odds of adverse pathology in men with localized disease undergoing radical prostatectomy. Serum 25-OH D may serve as a useful biomarker in prostate cancer aggressiveness, which deserves continued study.",
author = "Nyame, {Yaw A.} and Murphy, {Adam B.} and Bowen, {Diana K.} and Gregory Jordan and Ken Batai and Michael Dixon and Hollowell, {Courtney M.P.} and Stephanie Kielb and Meeks, {Joshua J.} and Gann, {Peter H.} and Virgilia Macias and Andre Kajdacsy-Balla and Catalona, {William J.} and Rick Kittles",
year = "2016",
month = "4",
day = "20",
doi = "10.1200/JCO.2015.65.1463",
language = "English (US)",
volume = "34",
pages = "1345--1349",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "12",

}

Associations between serum Vitamin D and adverse pathology in men undergoing radical prostatectomy. / Nyame, Yaw A.; Murphy, Adam B.; Bowen, Diana K.; Jordan, Gregory; Batai, Ken; Dixon, Michael; Hollowell, Courtney M.P.; Kielb, Stephanie; Meeks, Joshua J.; Gann, Peter H.; Macias, Virgilia; Kajdacsy-Balla, Andre; Catalona, William J.; Kittles, Rick.

In: Journal of Clinical Oncology, Vol. 34, No. 12, 20.04.2016, p. 1345-1349.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Associations between serum Vitamin D and adverse pathology in men undergoing radical prostatectomy

AU - Nyame, Yaw A.

AU - Murphy, Adam B.

AU - Bowen, Diana K.

AU - Jordan, Gregory

AU - Batai, Ken

AU - Dixon, Michael

AU - Hollowell, Courtney M.P.

AU - Kielb, Stephanie

AU - Meeks, Joshua J.

AU - Gann, Peter H.

AU - Macias, Virgilia

AU - Kajdacsy-Balla, Andre

AU - Catalona, William J.

AU - Kittles, Rick

PY - 2016/4/20

Y1 - 2016/4/20

N2 - Purpose Lower serum Vitamin D levels have been associated with an increased risk of aggressive prostate cancer. Among men with localized prostate cancer, especially with low- or intermediate-risk disease, Vitamin D may serve as an important biomarker of disease aggression. The aim of this study was to assess the relationship between adverse pathology at the time of radical prostatectomy and serum 25-hydroxyVitamin D (25-OH D) levels. Methods This cross-sectional study was carried out from 2009 to 2014, nested within a large epidemiologic study of 1,760 healthy controls and men undergoing prostate cancer screening. In total, 190 men underwent radical prostatectomy in the cohort. Adverse pathology was defined as the presence of primary Gleason 4 or any Gleason 5 disease, or extraprostatic extension. Descriptive and multivariate analyses were performed to assess the relationship between 25-OH D and adverse pathology at the time of prostatectomy. Results Eighty-seven men (45.8%) in this cohort demonstrated adverse pathology at radical prostatectomy. Themedian age in the cohort was 64.0 years (interquartile range, 59.0 to 67.0). On univariate analysis,men with adverse pathology at radical prostatectomy demonstrated lower median serum 25-OH D (22.7 v 27.0 ng/mL, P = .007) comparedwith their counterparts. On multivariate analysis, controlling for age, serum prostate specific antigen, and abnormal digital rectal examination, serum 25-OH D less than 30 ng/mL was associated with increased odds of adverse pathology (odds ratio, 2.64; 95% CI, 1.25 to 5.59; P = .01). Conclusion Insufficiency/deficiency of serum 25-OH D is associated with increased odds of adverse pathology in men with localized disease undergoing radical prostatectomy. Serum 25-OH D may serve as a useful biomarker in prostate cancer aggressiveness, which deserves continued study.

AB - Purpose Lower serum Vitamin D levels have been associated with an increased risk of aggressive prostate cancer. Among men with localized prostate cancer, especially with low- or intermediate-risk disease, Vitamin D may serve as an important biomarker of disease aggression. The aim of this study was to assess the relationship between adverse pathology at the time of radical prostatectomy and serum 25-hydroxyVitamin D (25-OH D) levels. Methods This cross-sectional study was carried out from 2009 to 2014, nested within a large epidemiologic study of 1,760 healthy controls and men undergoing prostate cancer screening. In total, 190 men underwent radical prostatectomy in the cohort. Adverse pathology was defined as the presence of primary Gleason 4 or any Gleason 5 disease, or extraprostatic extension. Descriptive and multivariate analyses were performed to assess the relationship between 25-OH D and adverse pathology at the time of prostatectomy. Results Eighty-seven men (45.8%) in this cohort demonstrated adverse pathology at radical prostatectomy. Themedian age in the cohort was 64.0 years (interquartile range, 59.0 to 67.0). On univariate analysis,men with adverse pathology at radical prostatectomy demonstrated lower median serum 25-OH D (22.7 v 27.0 ng/mL, P = .007) comparedwith their counterparts. On multivariate analysis, controlling for age, serum prostate specific antigen, and abnormal digital rectal examination, serum 25-OH D less than 30 ng/mL was associated with increased odds of adverse pathology (odds ratio, 2.64; 95% CI, 1.25 to 5.59; P = .01). Conclusion Insufficiency/deficiency of serum 25-OH D is associated with increased odds of adverse pathology in men with localized disease undergoing radical prostatectomy. Serum 25-OH D may serve as a useful biomarker in prostate cancer aggressiveness, which deserves continued study.

UR - http://www.scopus.com/inward/record.url?scp=84963595302&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963595302&partnerID=8YFLogxK

U2 - 10.1200/JCO.2015.65.1463

DO - 10.1200/JCO.2015.65.1463

M3 - Article

C2 - 26903577

AN - SCOPUS:84963595302

VL - 34

SP - 1345

EP - 1349

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 12

ER -